Allosteric effects of antagonists on signalling by the chemokine receptor CCR5

Biochemical Pharmacology

Volumn 74, Issue 6, 2007, Pages 891-897

  Haworth, Ben ^a   Lin, Hong ^a   Fidock, Mark ^b   Dorr, Pat ^b   Strange, Philip G ^a  

^a UNIVERSITY OF READING   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

35S GTP S binding; Antagonists; Chemokine receptor (CCR5); Chemokines; HIV; Receptor internalisation

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MONOCYTE CHEMOTACTIC PROTEIN 2; RANTES; SULFUR 35; UK 396794; UK 438235; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; ANIMALS; CHEMOKINE CCL5; CHEMOKINE CCL8; CHO CELLS; CRICETINAE; CRICETULUS; ENDOCYTOSIS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); RECEPTORS, CCR5; SIGNAL TRANSDUCTION;

EID: 34547691003     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.06.032     Document Type: Article

References (29)

1. Samson M., Labbe O., Mollereau C., Vassart G., and Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 35 (1996) 3362-3367
2. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 (1996) 1955-1958
3. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P.D., et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85 (1996) 1135-1148
4. Doranz B.J., Rucker J., Yi Y., Smyth R.J., Samson M., Peiper S.C., et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85 (1996) 1149-1158
5. Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381 (1996) 667-673
6. Pitcher J.A., Freedman N.J., and Lefkowitz R.J. G protein-coupled receptor kinases. Annu Rev Biochem 67 (1998) 653-692
7. Mueller A., Kelly E., and Strange P.G. Pathways for internalization and recycling of the chemokine receptor CCR5. Blood 99 (2002) 785-791
8. Blanpain C., Migeotte I., Lee B., Vakili J., Doranz B.J., Govaerts C., et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 94 (1999) 1899-1905
9. Baggiolini M., and Dahinden C.A. CC chemokines in allergic inflammation. Immunol Today 15 (1994) 127-133
10. Baggiolini M., Dewald B., and Moser B. Human chemokines: an update. Annu Rev Immunol 15 (1997) 675-705
11. Mueller A., Mahmoud N.G., Goedecke M.C., McKeating J.A., and Strange P.G. Pharmacological characterization of the chemokine receptor, CCR5. Br J Pharmacol 135 (2002) 1033-1043
12. Fatkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11 (2005) 1170-1172
13. Watson C., Jenkinson S., Kazmierski W., and Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 67 (2005) 1268-1282
14. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49 (2005) 4721-4732
15. Palani A., Shapiro S., Josien H., Bara T., Clader J.W., Greenlee W.J., et al. Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity. J Med Chem 45 (2002) 3143-3160
16. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 96 (1999) 5698-5703
17. Dorr P., Todd K., Irvine R., Robas N., Thomas A., Fidock M., et al. Site directed mutagenesis studies of CCR5 reveal differences in the interactions between the receptor and various CCR5 antagonists. Proceedings of the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. December 16-19, 2005, Washington (2005)
18. Lowry O., Rosebrough N., Farr A., and Randall R. Protein measurement with the folin phenol reagent. J Biol Chem 193 (1951) 265-275
19. Napier C., Sale H., Mosley M., Rickett G., Dorr P., Mansfield R., et al. Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol 71 (2005) 163-172
20. Dorr P., Dobbs S., Rickett G., Lewis B., Macartney M., Westby M., et al. In vitro evaluation of prolonged CCR5 occupancy by small molecule antagonists with anti HIV activity. Proceedings of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. September 14-17, 2003, Chicago (2003)
21. Milligan G., and Bond R.A. Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18 (1997) 468-474
22. Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 65 (2004) 2-11
23. Dorr P., Macartney M., Rickett G., Smith-Burchnell C., Dobbs S., Mori J., et al. UK-427,857, a novel small molecule HIV entry inhibitor is a specific antagonist of the chemokine receptor CCR5. Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections. February 10-14, 2003, Boston (2003)
24. Labrecque J., Anastassov V., Lau G., Darkes M., Mosi R., and Fricker S.P. The development of an europium-GTP assay to quantitate chemokine antagonist interactions for CXCR4 and CCR5. Assay Drug Dev Technol 3 (2005) 637-648
25. Strizki J.M., Xu S., Wagner N.E., Wojcik L., Liu J., Hou Y., et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 98 (2001) 12718-12723
26. Ehlert F.J. Analysis of allosterism in functional assays. J Pharmacol Exp Ther 315 (2005) 740-754
27. Kenakin T., Jenkinson S., and Watson C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319 (2006) 710-723
28. Xu L., Wojcik N., and Strizki J.M. Antagonism of the CCR5 receptor by SCH-C leads to elevated beta-chemokine levels and receptor expression in chronically treated PBMC cultures. Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002, Seattle (2002)
29. Penny M., Myrand S., Lin C., Boucher M., Man M., and James I. Pharmacogenetic analysis of polymorphisms in the chemokine receptors CCR5 and CCR2 in the clinical development of a CCR5 antagonist (UK-427,857) for the treatment of HIV/AIDS. FDA Science Symposium. February 20, 2004, Washington (2004)